Zobrazeno 1 - 5
of 5
pro vyhledávání: '"D H, Oette"'
Autor:
J C, Yau, J A, Neidhart, P, Triozzi, S, Verma, J, Nemunaitis, D P, Quick, D G, Mayernik, D H, Oette, F A, Haynes, J, Holcenberg
Publikováno v:
American journal of hematology. 51(4)
This is a double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of granulocyte-macrophage colony-stimulating-factor (GM-CSF) after dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP). Fifty-six patients wi
Autor:
E C, Guinan, Y S, Lee, K D, Lopez, S, Kohler, D H, Oette, E, Bruno, H, Kozakewich, D G, Nathan, R, Hoffman
Publikováno v:
Blood. 81(7)
Amegakaryocytic thrombocytopenia (AMT) is a rare and often fatal disorder of infancy and childhood presenting with isolated thrombocytopenia that progresses to marrow failure. The defect in thrombopoiesis is not well understood nor is the etiology of
Autor:
L E Sarmiento, James A. Neidhart, C Stidley, A Mangalik, S L Tebich, F B Oldham, J E Pfile, D H Oette
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 10(9)
PURPOSE This trial evaluated the optimum dosing regimen for recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) to support a dose-intensive chemotherapy regimen given without progenitor cell replacement. PATIENTS AND METHO
Publikováno v:
Blood. 76(6)
Nine pediatric patients (median age, 8 years; range, 0.7 to 19 years), eight with refractory aplastic anemia and one with newly diagnosed aplasia, were enrolled in a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating fact
Publikováno v:
Blood. 73:694-699
Fifteen patients with refractory aplastic anemia or agranulocytosis received treatment with recombinant human granulocyte-macrophage-colony- stimulating factor (rhGM-CSF) in doses from 4 to 64 micrograms/kg/d by continuous intravenous (IV) infusion.